Trial Profile

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Rituximab (Primary) ; Sonrotoclax (Primary) ; Venetoclax
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms CELESTIAL-RRCLL
Sponsors BeOne Medicines

05 Nov 2025 Planned End Date changed from 31 Dec 2032 to 1 Dec 2031.
06 Aug 2025 According to BeiGene media release, first patient has been enrolled.
13 Jun 2025 Planned initiation date changed from 1 May 2025 to 1 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com